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Abstract
Background: Despite reported antiproliferative activity of vitamin A and its common use for cancer, there is no
comprehensive synthesis of its safety and efficacy in lung cancers. To address this issue we conducted a systematic review
of the safety and efficacy of vitamin A for the treatment and prevention of lung cancers.
Methods and Findings: Two independent reviewers searched six electronic databases from inception to July 2009 for
clinical, observational, and preclinical evidence pertaining to the safety and efficacy of vitamin A and related retinoids for
lung cancers. 248 studies were included for full review and analysis. Five RCTs assessed treatment of lung cancers, three
assessed primary prevention, and three looked at secondary prevention of lung cancers. Five surrogate studies, 26 phase I/II,
32 observational, and 67 preclinical studies were also included. 107 studies were included for interactions between vitamin
A and chemo- or radiation- therapy. Although some studies demonstrated benefits, there was insufficient evidence overall
to support the use of vitamin A or related retinoids for the treatment or prevention of lung cancers. Retinyl palmitate
combined with beta carotene increased risk of lung cancer in smokers in the large CARET trial. Pooling of three studies
pertaining to treatment and three studies on secondary prevention revealed no significant effects on response rate, second
primary tumor, recurrence, 5-year survival, and mortality. There was a small improvement in event free survival associated
with vitamin A compared to controls, RR 1.24 (95% CI 1.13–1.35). The synthetic rexinoid bexarotene increased survival
significantly among a subset of patients in two RCTs (p,0.014, ,0.087).
Conclusions: There is a lack of evidence to support the use of naturally occuring retinoids for the treatment and prevention
of lung cancers. The rexinoid bexarotene may hold promise for use among a subset of patients, and deserves further study.
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Introduction
Lung cancers account for 12% of cancers globally and are the
most common cancer type second only to non-melanoma skin
cancer [1]. Lung cancers are the leading cause of cancer mortality,
with an estimated 159,390 deaths in 2009 in the United States
alone [1,2]. Because of their prevalence, severity, and lack of
effective treatment, it is crucial to find new interventions for the
treatment and prevention of this disease.
Vitamin A is the generic term for a family of related compounds
consisting of retinol and its derivatives, the retinoids [3].
Historically, natural retinoids have been used in the treatment of
lung cancers since the late 70’s when the first human trials were
conducted [4,5,6,7] on the basis of antiproliferative effects specific
to epithelial tissues and tumors [8,9,10,11]. The development of
synthetic retinoids occurred subsequently in an attempt to retain
vitamin A’s antiproliferative effects specific to epithelial tissue
while avoiding dose limiting side effects such as skin and liver
toxicity [4,12]. A recent survey of lung cancer patients found that
54% used complementary and alternative therapies, with vitamin
combinations being the most common, at 17% [13]. Additionally,
out of ten natural health products (NHPs) assessed during an initial
scoping review of the literature for this project, vitamin A had the
greatest volume and quality of evidence around its use in lung
cancers.
The body obtains vitamin A from two sources: preformed vitamin
A (retinol and retinal in the form of retinyl esters), and provitamin A
carotenoids (beta carotene, alpha carotene, beta cryptoxanthin)
[14,15]. Preformed vitamin A is found in cod liver oil, butter, eggs,
animal products, and fortified grains [14]. Provitamin A carotenoids
are found in highly pigmented vegetables such as carrots, squash,
yams, and green leafy vegetables [14]. Once in the body, retinol is
ultimately converted into retinoic acid and its isoforms, collectively
known asretinoids[14]. VitaminA isresponsiblefor the maintenance
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21107of epithelial tissues such as skin,mucus membranes, and lung tissue; it
supports immune function; and plays a key role in mediating vision
[16,17].
Provitamin A carotenoids, particularly beta carotene, have also
been studied for the prevention of lung cancers. Beta carotene acts
in part through its conversion to vitamin A in the intestine and
liver, however, it also independently possesses singlet oxygen
quenching activity. It has been estimated that up to 88% of beta
carotene is converted to retinyl esters in the intestinal wall, while
up to 30% enters lymphatic circulation unchanged [18,19,20].
Beta carotene that reaches the liver undergoes further conversion
to retinol, however a small percentage enters the blood unchanged
[18]. The absorption and conversion of beta carotene to retinol is
limited by several factors, including dose administered, with
enzymatic saturation occurring at higher doses; the surrounding
food matrix; the antagonistic effect of other carotenoids and
vitamin A in the diet; and the vitamin A status of the individual
[18,21]. Beta carotene can correct vitamin A deficiency but it does
not achieve the supraphysiological serum retinol levels attained by
direct vitamin A supplementation. As such it does not possess the
toxicity characteristic of high dose vitamin A supplementation;
rather it results in orange discoloration of the skin [19]. At supra-
repletion doses, the physiological activity of beta carotene beyond
that of restoring vitamin A levels is likely due to its independent
redox function or effects on cellular communication [22,23].
Therefore, vitamin A may have a function in lung cancers distinct
from that of beta carotene. For this reason, and since therapeutic
use of vitamin A in lung cancers typically involves induction of
supraphysiological serum levels, we only focused on the use of
preformed vitamin A and retinoids for the purposes of this review.
Retinoid compounds consist of a basic structure of four isoprenoid
units joined in a head-to-tail manner [24]. A large amount of
variability exists between retinoids, and synthetic derivatives, which
differ considerably in structure from the naturally occurring retinoids,
have been developed in the hopes of avoiding some of the toxicity
associated with the latter. Retinoids may be selective toward the two
major retinoid receptors, retinoic acid receptor (RAR) and retinoid X
receptor (RXR), or non selective pan-agonists [25]. First generation,
or naturally occurring/physiological retinoids are derived from
retinyl palmitate, C36H60O2, and include the isomers of retinoic
acid such as 13-cis retinoic acid (13 CRA),9-cisretinoic acid (9 CRA),
and all-trans retinoic acid (ATRA) [14,25]. Tretinoin (ATRA) and
isotretinoin (13 CRA) are pharmaceutically produced versions of
these. Alternately, novel synthetics that do not exist naturally have
been designed for use in cancer (bexarotene and fenretinide) and
other proliferative conditions (etretinate) [26,27]. The two most
common supplemental forms of vitamin A are retinyl palmitate and
retinyl acetate [14]. Table 1 outlines the classification of major
retinoids and their primary clinical uses [16,28,29,30,31].
Retinoid molecules possess an antiproliferative effect at the cellular
level via growth arrest signaling, promotion of differentiation, and
induction of apoptosis [25]. Most retinoid activities are mediated by
nuclear receptors: the retinoic acid receptor (RAR) and the retinoid X
receptor (RXR), with subtypes a,ß ,a n dc [25]. These receptors
function as ligand-regulated transcription factors that modulate gene
expression patterns [32]. The exact mechanisms by which these
receptors exert their downstream effect are complex and as yet
incompletely elucidated, however they are thought to activate
pathways that converge on G1 cell cycle arrest [28]. Retinoic acid
has also been shown to downregulate markers of proliferation such as
hTERT and cyclins D1 and 3 [33,34], markers of DNA damage such
as 8-oxo dGuo [35], and growth factors such as epidermal growth
factor receptor (EGFR) and vascular endothelial growth factor
(VEGF), potentially inhibiting tumor growth, angiogenesis, and
metastasis [28,36]. Tumor progression has been associated with
decreased RARß expression, as a result it has also been proposed that
retinoic acid inductible RARß may act directly as a tumor suppressor
[25]. Retinoids are also thought to modulate additional targets such
Table 1. Retinoid Classification.
Common name
Generic name (Brand
name if applicable) Classification Primary Use
Physiological retinoids
First Generation
All trans retinoic acid tretinoin classical* natural or synthetic;
RAR agonist [29,30]
Acute promyelocytic
leukemia (APL) [5]
9 cis retinoic acid alitretinoin nonclassical{ natural or synthetic;
RAR + RXR agonist [29,30]
Kaposi’s sarcoma [30]
13 cis retinoinc acid isotretinoin (Accutane) classical natural or synthetic;
RAR agonist [25]
Acne vulgaris [5]
Synthetic retinoids
Second Generation
Same as generic name etretinate (Tegrison) OR acretin
(Soriatane) its metabolite
synthetic, receptor dependent,
aromatic retinoid
Psoriasis [27,31,32]
Third Generation
Same as generic
name
bexarotene (Targretin) synthetic receptor dependent;
RXR agonist (rexinoid) [25]
Cutaneous T-cell
lymphoma [5,28,33]
4-HPR (N-4 hydroxyphenyl
retinamide)
fenretinide synthetic RAR agonist and receptor
independent retinoid (atypical{ retinoid) [30]
Breast cancer
chemoprevention [30]
*Classical refers to retinoic acid receptor (RAR) agonism.
{Nonclassical refers to rexinoid receptor (RXR) agonism.
{Atypical refers to receptor independent retinoids.
doi:10.1371/journal.pone.0021107.t001
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cyclooxygenase-2 (Cox-2), nuclear factor-kB, ubiquitination, tumor
necrosis factor-a, c-Myc, Ap-1, and cell surface death receptors [37].
Preneoplastic and neoplastic diseases successfully treated with
retinoids include oral leukoplakia, cervical dysplasia and xeroderma
pigmentosum (premalignant), and acute promyelocytic leukemia
(APL), a malignant condition characterized by altered signalling
through both the promyelocyte leukemia protein (PML) and
retinoic acid receptor a (RARa) [25,38]. Modest but encouraging
results have been found in the treatment of other cancer types
including: head and neck cancer, cutaneous T-cell lymphoma, and
neuroblastoma [39,40], with increased survival (p,0.01) and
reduced rates of second primary tumors (p=0.005) demonstrated
in some studies [41,42]. The utilization of retinoids for the
chemoprevention of lung cancers has been controversial, however,
exemplified in the findings of the large CARET trial (Beta Carotene
and Retinol Efficacy Trial) [43].
Given the range of vitamin A utilization and the possibility for
harm in lung cancers, all levels of evidence, clinical and preclinical,
were included in this synthesis of current knowledge pertaining to
the safety and efficacy of vitamin A and its natural and synthetic
derivatives for the treatment or prevention of lung cancers. We
also assessed for potential interactions between Vitamin A and
retinoids with chemotherapy and radiation treatment.
Methods
Search Strategy
We searched the following electronic databases for all levels of
evidence pertaining to vitamin A and lung cancer: Pubmed,
EMBASE, CINAHL, AltHealthWatch, the Cochrane Library,
and the National Library of Science and Technology, from
inception to the end of July 2009. We used a broad based MeSH
and keyword approach combining clinical (lung cancer) and
therapeutic (vitamin A) search terms. Separate searches were
conducted independently by HF and DAK. After initial searches
were completed, the scope of the review was expanded to include
keywords associated with synthetic and naturally occurring
retinoids. This additional search was conducted based on the
premise that retinoids are derivatives of vitamin A that retain a
similar mechanism of action while ostensibly posing less risk of
toxicity and furthermore are used clinically. Table S1 provides
details on the search terms and strategy used to collect the records
for screening from both searches employed.
A third search was conducted in Pubmed and EMBASE from
inception to the end of October 2009 to identify articles pertaining
to vitamin A and interactions with drugs used in lung cancer
treatment and/or radiation therapy, irrespective of cancer type.
Evidence of interactions were from clinical trials, observational
studies, case reports, and preclinical studies where chemotherapy
drugs and/or radiation therapy for lung cancers were assessed.
Study Selection
Screening of studies was initially conducted based on title review.
In the event of uncertainty, abstracts and/or full texts were also
reviewed. Only English language publications were included. For
inclusion, human trials had to assess the efficacy of natural or
synthetic retinoids in lung cancers for the purposes of treatment,
primary or secondary prevention, reduction of side effects and
toxicities associated with chemo- or radiation- therapy, or assess for
potential interactions with thesetherapies. Uncontrolled human trials
were included, however they were evaluated separately, and in the
absence of a comparator arm, determination of positive or negative
outcome was based on the authors’ interpretation of their findings (i.e.
self assessed). Biomarker studies in humans were included if they
examined endpoints directly related to lung cancer risk or
pathogenesis. All types of lung cancers (SCLC, NSCLC, mesothe-
lioma) were included.
In order to be included, observational studies had to employ an
objective measure of preformed vitamin A status, such as serum,
plasma, or lung tissue retinol levels, and had to examine the risk of
lung cancers either prospectively or be conducted in patients with
lung cancers comparing vitamin A status to patients without cancer.
Due tothe high possibilityforconfounding,studies examiningdietary
intake alone were excluded from analysis. Observational studies
examining intake of supplemental vitamin A were also included.
For inclusion, preclinical studies had to be conducted in lung
cancer models and examine either anticancer effects of vitamin A or
related retinoids, or their interaction with conventional chemo- or
radiation- therapy. Preclinical studies were categorized by results as
positive, negative, neutral, or mixed. The term ‘‘positive’’ designates
studiesthatfoundsignificantanticancereffectsfromatleastoneofthe
retinoids tested in models of lung cancers, alone or additively with
other agents; ‘‘negative’’ designates studies that found significant pro-
carcinogenic effects alone or in combination with other agents; and
‘‘neutral’’ designates studies that found no significant beneficial effect,
nor any evidence of harm. In the absence of reported levels of
significance, the authors’ interpretation was used to guide classifica-
tion. Studies examining surrogate markers were includedz only if the
surrogates related directly to lung cancer risk or pathogenesis.
Data Extraction and Quality Assessment
Data extraction forms were piloted using duplicate review to
assess inter-researcher reliability. Upon completion of data
extraction in duplicate for fifty percent of human level studies,
there were no major inconsistencies, and further duplication of
data extraction was found to be redundant. Extraction sheets were
prepared partly based on the Consolidated Standards of Reporting
Trials (CONSORT) statement, the Newcastle-Ottawa scale
(NOS), and the Score for Assessment of Physical Experiments
on Homeopathy (SAPEH) for clinical trials, observational studies,
and preclinical studies, respectively [44,45,46]. We also extracted
data on study design, patient characteristics, exposures or
interventions, and outcomes. Randomized controlled trials were
additionally assigned a quality score based on the Jadad criteria
[47]. Interactions related articles were extracted similarly and
analyzed for information specifically pertaining to interactions.
Statistical Analysis
For randomized controlled trials, outcome data were pooled
using random effects models weighted by the inverse variance in
Comprehensive Meta-analysis Version 2, Biostat, Englewood, NJ,
USA. Results are presented as risk ratios with 95% confidence
intervals. Heterogeneity was assessed using the I
2 statistic.
Results
Search Results
The combined searches identified 7257 records for screening. A
total of 141 studies were included for efficacy analysis. Five RCTs
were included for the treatment of lung cancers, three RCTs
looked at primary prevention, and three RCTs looked at
secondary prevention of lung cancers. Five surrogate studies and
26 phase I/II studies were included. Thirty-two observational and
67 preclinical studies were also included. For the interactions
component, 107 studies were included for full review and analysis.
See Figure 1 for a flowchart of studies included in the review.
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Sixty-seven preclinical studies of retinoids in lung cancer models
were included for analysis. These studies were included in order to
more clearly establish the biological rationale for retinoid use in lung
cancers. Of the 67 studies, 54 showed results in favour of the retinoids
tested, four showed mixed results, seven showed no effect, and two
showed negative effects. Amongst the positive preclinical findings, the
following anticancer effects were identified and synthesized: inhibi-
tion of growth and proliferation (n=33 occurrences), proapoptotic
(n=15), chemopreventive (n=14), anti-metastatic, anti-angiogenic,
or anti-invasive (n=7), lung cancer specific cytotoxicity (n=3).
Conversely, one study suggested a co-carcinogenic activity for
supplemental retinyl palmitate when combined with 20-methylcho-
lanthrene (20-MCA) [48] and one study showed a potential pro-
angiogenic effect with increased VEGF levels [49]. Refer to Table
S2 for a detailed summary of preclinical evidence.
Biomarker Trials
Inhumans,retinoidsmaymodulatemediatorsofproliferationand
some that are associated with lung cancer progression. An
uncontrolled trial in early stage NSCLC patients suggested that
bexarotene may modulate expression of biomarkers such as cyclins
Figure 1. Flowchart of Literature Search and Study Selection.
doi:10.1371/journal.pone.0021107.g001
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[33,50,51,52]. Of four trials investigating surrogate endpoints in
high risk populations, two showed positive results including
decreased expression of hTERT, a marker of proliferation, in
bronchiolar tissue, and increased RARß expression (decreased
expression of RARß has been associated with lung cancer
development) [34,53]. These trials used fenretinide and 13 CRA,
respectively. Two of the four trials showed no significant effect on
sputum atypia and bronchial cell metaplasia/dysplasia, also
associated with lung cancer [54,55]. Additionally, one observational
study found no correlation between serum retinol and leukocyte 8-
oxo-dGuo, a marker of DNA damage [35].
Phase I/II Trials
Findings from the 26 included uncontrolled phase I or II trials
suggest limited clinical benefit of vitamin A when used independently
of chemotherapy. Of the 26 studies analyzed, 13 demonstrated
positive results on response rates and/or survival time and 13 showed
no significant effects (see Table S3). Of the positive trials, five used
ATRA, four used 13 CRA, three used bexarotene, and two used
retinol palmitate. Of the trials with no significant effect, five used 13
CRA, three used bexarotene, three used ATRA, one used 9 CRA
and one used retinol; there were no major differences in dose ranges
used between the studies with positive and negative findings. These
phase I/II trials were conducted in patients with advanced stages of
lung cancers, and in most cases, retinoids were used in conjunction
with various chemotherapies including: docetaxel and capecitabine,
cisplatin, etoposide, vindesine, mitomycin-C, carboplatin, gemcita-
bine, vinorelbine, 5-fluorouracil, interferon, and interleukin-2.
Conversely, chemotherapy was rarely used in the trials showing no
significant effects. None of the trials demonstrated disease exacerba-
tion when vitamin A or retinoids were employed for treatment.
Controlled Observational Studies
Thirty-two controlled observational studies were included for
analysis. Seven of the studies were prospective, 16 were
retrospective, and 9 were cross-sectional. Of all the observational
studies included, nearly half (n=15) found an inverse relationship
between serum retinol levels and risk of lung cancers (longitudinal
studies) and/or current diagnoses of lung cancers (cross-sectional
studies). See Tables S4 and S5.
Controlled Clinical Trials
Treatment. Five interventional RCTs tested retinoids
(bexarotene and 13 CRA) in either small cell or non-small cell
lung cancers (see Tables S4 and S5) [56,57,58,59,60]. Of these,
one trial comparing 13 CRA + IL-2 versus IL-2 alone demonstrated
improvements in immunological parameters and a decrease in
VEGF. In this trial, a trend towards improvement was also seen in
progression free survival (PFS): 39.3% in the treatment arm versus
30.4% of controls were progression free at 42 months, with a
median PFS of 28.45 months versus 12.35 months, treatment versus
control (HR 0.7356, 95% CI 0.46–1.163, p=0.185) [56]. Meta
analysis of three trials measuring response rates found no significant
effect overall, relative risk RR 0.84, (95% CI 0.68–1.03,
I
2=40.4%). For one study that reported response rates in terms
of complete response, partial response, progressive disease, or
disease stabilization, the response rate was calculated based on the
number of complete and partial responses [60]. See Figure 2.
Two RCTs examining adjuvant bexarotene therapy found
significant survival benefits among a subset of patients who experienced
Grade 3/4 hypertriglyceridemia ($5x upper limit of normal),
compared to the control group: Ramlau reported that these patients
had median survival of 12.3 mo compared to 9.9 mo in the control
group (p=0.087), while Blumenschein reported median survival of
12.4 mo compared to 9.2 mo in similar patients (p=0.014) [57,58].
These responsive patients that represented approximately 30–40% of
the treatment group also had a higher incidence of side effects
including skin rash and hypothyroidism, suggesting that hypertriglyc-
eridemia may be a surrogate of greater systemic biochemical sensitivity
to the effects of bexarotene [57]. Conversely, of the patients receiving
bexarotene and who did not experience Grade 3/4 hypertriglyceri-
demia, a worse treatment response was reported, with significantly
shorter survival than the placebo groups (p,0.0001 for both),
highlighting the need to efficiently identify responders [57,58], Rizvi
also examined bexarotene, however the study was prematurely
terminated due to poor enrollment [59].
Primary Prevention. Three controlled clinical trials were
found pertaining to vitamin A and primary prevention of lung
cancers [43,61,62]. All of the clinical trials used retinyl palmitate.
Two trials showed no significant effects on lung cancer prevention
overall [61,62], however, one of these did find a significantly
decreased risk of mesothelioma only as separate from SCLC and
NSCLC, RR 0.24 (95% CI 0.07–0.86) [61]. These trials were not
pooled due to heterogeneity in the reporting of results. The large
Carotene and Retinol Efficacy Trial (CARET), however, found
significant increases in lung cancer incidence from combined
treatment with retinyl palmitate and beta carotene when
administered in high risk populations. Trial results demonstrated
an increase in overall lung cancers, (RR 1.28; 95% CI 1.04-1.57).
Subgroup analysis showed higher risk in asbestos workers (RR
1.40, 95% CI: 0.95–2.07), and current heavy smokers (RR 1.42,
95% CI: 1.07–1.87), while finding a non significant reduction in
risk amongst smokers who had already quit at randomization (RR
0.80, 95% CI: 0.48–1.31) [43]. Relative risk of death from all
causes was 1.18 (95% CI: 1.02–1.37), death from lung cancers
1.46 (95% CI 1.07–2.00), and death from cardiovascular disease
1.26 (95% CI 0.99–1.61) [43]. There was no evidence of increased
risk of other cancer types.
Secondary Prevention. Three controlled trials for the
secondary prevention of lung cancers were included [63,64,65].
Lippman found no significant effects overall, however, lung cancer
recurrence and all cause mortality were significantly increased in
current smokers receiving isotretinoin compared to placebo, HR
3.11 (95% CI 1.00–9.71) and 4.39 (1.11–17.29) respectively [63].
Meta analysis of these three RCTs for secondary prevention
showed no significant effects for vitamin A on second primary
tumor (RR 1.18, 95% CI 0.72–1.94, I
2=78.7%), recurrence (RR
0.94, 95% CI 0.74–1.20, I
2=47.1%), 5-year survival (RR 1.00,
95% 0.97–1.02, I
2=0%), and death (RR 0.94, 95% CI 0.78–1.15,
I
2=0%). There was a small but significant improvement in event
free survival associated with vitamin A compared to controls, RR
1.24 (95% CI 1.13–1.35, I
2=0%), based on data from two RCTs.
See Figure 2.
Safety and Risks Associated with Use
Adverse Events. In controlled clinical trials, the most common
side effects observed were grade I-II mucocutaneous symptoms
symptoms including dry skin, rash, conjunctivitis, and chelitis, rever-
sible hypothyroidism, and hyperlipidemia, especially hypertrigly-
ceridemia. In the two controlled studies of bexarotene that reported
incidence, between 63–66% of treated patients experienced hyper-
triglyceridemia compared to 1.3–2.0% of control groups, and between
12–25% experienced hypothyroidism compared to 0.3–0.7% of the
control groups [58,60]. Hypertriglyceridemia was usually manageable
with antilipid therapy, however in some cases dose reduction was
necessary to prevent patient withdrawal from the study due to toxicity
(up to 18%) [58]. Up to 24% of patients treated with bexarotene
Vitamin A and Lung Cancer
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replacement therapy [58].
In the Phase I/II trials, the most common side effects observed
were mucocutaneous symptoms (occurring amongst most patients in
someofthetrials);hyperlipidemia,inparticularhypertriglyceridemia,
ranging from under 44 to 86% in frequency; and elevated liver
function tests (LFTs), in up to 54%. Hypertriglyceridemia and
elevated liver enzymes were most often a grade I/II severity, but
reached grade III/IV in some cases; hypertriglyceridemia and
elevated liver enzymes were reversible upon dose reduction or
Figure 2. Forest Plots: Pooled Results of RCTs for the Treatment or Prevention of Lung Cancer.
doi:10.1371/journal.pone.0021107.g002
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symptoms, headaches, myalgia/arthralgia, and fatigue. Hematolog-
ical toxicities occurred in trials combining retinoids with chemother-
apy, however, these were not common in trials of retinoids alone,
suggesting chemotherapy as the causative agent.
Dose Limiting Toxicities. In a Phase I trial of ATRA, dose
limiting toxicities (DLTs) of mucocutaneous symptoms, headache,
fatigue, gastrointestinal symptoms, myalgia, and confusion, were
established. These DLTs occurred at 150 mg/m
2 ATRA in
conjunction with cisplatin and etoposide [66]. In a phase I trial of
bexarotene, DLTs included one case of a pain syndrome and one
case of increased creatinine kinase (CK), however the maximum
tolerated dose (MTD) was not reached [67]. Yet another phase I trial
using escalating doses of 200, 300, and 400 mg/m
2 bexarotene did
not reach a MTD as defined at outset, which was the dose level
immediately below the dose level at which 2 patients of a dose level
experienced DLT during their first cycle [68].
Interactions
Table S6 provides an overview of the effects of retinoid/
chemotherapeutic drug combinations in specific cell lines in vitro.
The effects summarized include a combination index (CI) between
the two substances, if reported, and when no CI was reported an
account of either a positive or negative impact on neoplastic cell
growth from the combination is provided in the table.
Emphasis is placed here on the pharmacokinetics changes and
adverse events reported in the literature of the various vitamin A
forms and the chemotherapy drugs used in the treatment of lung
cancer. Case reports were also reviewed however, no relevant
information could be garnered on interactions and these did not
enhance the results, and thus are not reported.
Fenretinide
One phase I study found a reduced Cmax and AUC on day 8 for
fenretinide in combination with cisplatin and paclitaxel, however, in
the absence of serum data, it was not possible to determine whether
the reduction was due to reduced absorption or increased elimination
kinetics [69]. Significant nyctalopia (night blindness), causing
treatment delays, was also reported with the combination of
fenretinide/cisplatin/paclitaxel. Nyctalopia has also been reported
with isotretinion and is thought to develop due to hypovitaminosis A,
which results in a reduction in rhodopsin for the photoreceptors [70].
Bexarotene
Dose limiting toxicities for bexarotene have not been reported
up to 500 mg/m
2, however, at 600 mg/m
2 and above cases of
hypertriglycemidemia leading to acute pancreatitis have been
reported [71].
All-trans retinoic acid (ATRA)
A larger body of research has been conducted regarding the
pharmacokinetics of ATRA. Absorption of oral ATRA is variable
and highly dependent upon a high fat content in the intestinal
lumen, as ATRA is almost insoluble in an aqueous environment
[72]. Continuous dosing of ATRA has been found to accelerate
elimination of ATRA and an ‘‘on-off’’ the dosing schedule is
suggested to avoid the increased elimination [72]. ATRA has been
found to induce Retinoic Acid Syndrome (RAS) in APL and AML
patients, which can be fatal in some.
13cis – retinoic acid (13CRA)
Waladkhani and Clemens studied the pharmacokinetics of 13
CRA along with interferon a in cancer patients. Their results
demonstrated an increase conversion to the less potent metabolite,
4-oxo 13CRA, in cancer patients versus healthy volunteers
possibly through the up regulation of CYP induced by interferon
a [73]. 13CRA was found to decrease elimination of paclitaxel and
increase the AUC of the metabolite 6-alfa-hydroxytaxol [74].
Discussion
Although vitamin A and related retinoids have been widely used
for the treatment and prevention of lung cancers, our review
suggests that there is a lack of evidence to support this use.
Preliminary evidence including preclinical and observational
studies has shown promising results with respect to lung cancer
pathogenesis and disease risk, respectively, however these effects
have not translated to human interventional settings. Encouraging
preliminary results were found by Pastorino et al. in a setting of
secondary prevention of NSCLC following surgical resection as
well as by de Klerk et al in primary prevention of mesothelioma,
but these have not been replicated by other groups [61,64]. The
CARET trial found adverse effects on overall lung cancer risk
among smokers and asbestos workers, and this seems to be
supported by similar effects among current smokers in the trial by
Lippman [43,63].
There is a lack of RCTs investigating retinoids for lung cancer
treatment; a single trial exists showing clinical benefit when 13
CRA, a naturally occurring retinoid, was combined IL-2, and this
on surrogate immune parameters and levels of VEGF only. Two
RCTs investigating the synthetic rexinoid bexarotene have shown
significant survival benefits in a third of patients manifesting
hypertriglyceridemia as a surrogate of sensitivity, but worse
outcomes in non-responders [57,58]. Further research is required
to elucidate the best genetic predictors or biochemical surrogates
of responsiveness and to confirm these post hoc findings before
bexarotene can be recommended for wider clinical use [75]. At
present these results should not be extrapolated to other retinoids
due to the considerable biochemical differences between them,
however, any future research investigating retinoids, classical or
not, should adopt a similar strategy of identifying a surrogate of
responsiveness among a subgroup of patients.
The reasons for the observed divergence and the lack of
applicability between preclinical findings and the clinical setting
are not clear. It is possible that the appropriate subset of patients
who might benefit from retinyl palmitate or other retinoids has not
been adequately identified by the clinical research to date, as has
been done in the case of bexarotene. Alternately, this divergence
may arise from the inherent differences between preclinical and
clinical research. One theory has been suggested that preclinical
lung cancer models induced by exposure to single carcinogens such
as the nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
(NNK) do not accurately mimic the effects of a complex carcinogen
such ascigarettesmoke,well accepted to be the most commoncause
of lung cancer [76]. This inconsistency has been confirmed, for
instance,instudies ofselenium comparingchemopreventioninboth
complex- or single- carcinogen lung cancer models, wherein
selenium was able to prevent lung tumors induced by NNK, but
not those caused by exposure to tobacco smoke [76,77].
With respect to observational evidence, it is possible that serum
retinol may be a biomarker of other active anticancer substances
in the diet or of an overall ‘‘healthy’’ dietary pattern. In this case,
interventions with vitamin A alone would be expected to fail. The
biomarker theory is even more applicable to beta carotene which
correlates more directly than serum retinol with intake of fruits
and vegetables and what is considered an overall health-promoting
diet rich in a complex array of chemopreventive substances such as
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may explain in part the failure of vitamin A as an interventional
agent, and is especially true insofar as beta carotene contributes to
normal (but not supraphysiological) vitamin A status.
Importantly, CARET, the largest chemoprevention trial to date
of vitamin A and lung cancers, found a significantly increased risk
of lung cancers in the retinol and beta carotene arm [43]. This
trial, consisting of 18,314 current and former smokers and asbestos
workers at high risk of lung cancers, was stopped early due to
interim results showing increased lung cancer risk in the active
arm (retinol and beta carotene), RR 1.28 (1.04–1.57) [43]. When
reported according to the prespecified weighted analysis, this
increased to RR 1.36 (95% CI 1.07 – 1.73) [80]. Follow up results
found that the risk of lung cancers and overall risk of death were
elevated up to six years after the intervention was discontinued,
with greatest impact occurring in women [81]. Adjustment for
baseline beta carotene levels did not modify the elevated risks
associated with active treatment, and the effect retinol and beta
carotene was greatest several years after beginning consumption
[80].
A biomarker study was conducted in a small subgroup of the
CARET population to determine the effect of supplementation on
target tissue levels: bronchoalveolar lavage showed that while tissue
levels of beta carotene increased significantly with supplementation,
retinol levels did not [82]; serum levels increased for both [83]. This
suggests that beta carotene, independent of its provitamin A activity,
may be the culprit responsible for the deleterious effect on lung
cancers observed in this trial. This hypothesis is supported by similar
findings from the large Finnish Alpha Tocopherol Beta Carotene
(ATBC) trial, conducted in 29,133 male smokers for 5 to 8 years.
Investigators found that supplementation of 20 mg beta carotene
without vitamin A increased incidence of lung cancers by 16%
compared to those not receiving beta carotene, RR 1.16 (95% CI
1.02 – 1.33) [84]. Serum retinol levels rose only 6% compared to
placebo in those receiving beta carotene supplementation (p=0.03)
[85]. This increase in risk is roughly comparable to the 28% effect
seen in CARET.
While the mechanism for the detrimental effects observed have
not been fully elucidated, it is hypothesized that under conditions of
high oxidative stress and exposure to lung irritants such as those
associated with exposure to cigarette smoke and asbestos, certain
antioxidants may in fact act as conditional pro-oxidants
[22,86,87,88]. According to the conditional pro-oxidant hypothesis,
the activity of an antioxidant depends on its redox potential in
relation to other pro- and anti- oxidants in its microenvironment.
Carotenoids are particularly vulnerable to such oxidation due to
their long chains of conjugated double bonds, and are known to
concentrate in the lungs [89,90,91]. New evidence suggests that
carotene breakdown products (CBPs) produced by high dose
administration under conditions of oxidative stress may act as pro-
oxidants, impairing mitochondrial function and resulting in cellular
damage, thereby predisposing to carcinogenesis [22,91].
Limitations of the chemoprevention studies listed here include
lack of a single-agent intervention arm in CARET, and lack of a
placebo arm in the Western Perth study to distinguish the
potentially differing effects of beta carotene and retinol. CARET
also used a synthetic form of beta carotene. As discussed above,
while beta carotene is a precursor to retinol in the body, it is
nonetheless physiologically distinct in its own right, possessing
redox activity independent of vitamin A [90]. Also, while CBPs
have been shown to impair mitochondrial function, preliminary
evidence suggests that retinol may be an essential response
modifier and cofactor of mitochondrial energy production [92].
The limitations of these chemoprevention trials, however, impede
our ability to draw any definite conclusions about the differential
effects of beta carotene and retinoids on lung cancers in humans.
Notably, a 2008 systematic review and meta- analysis focused
exclusively on beta carotene in relation to cancer risk. Investigators
screened 22,994 records and included six RCTs plus 30
prospective observational studies [223]. The RCTs included in
this review, three of which have already been described above,
were: 1) the Carotene and Retinol Efficacy Trial (CARET) [43]; 2)
the Alpha Tocopherol Beta Carotene (ATBC) study [94]; 3) the
Physicians’ Health Study (PHS) [95]; 4) the Western Perth,
Australia study [61]; 5) the Women’s Health Study [96]; and 6) the
Linxian General Population trial [62]. The pooled RR for studies
comparing beta carotene supplements to placebo (n=3) was 1.10
(95% CI 0.89 – 1.36) [93]. In trials conducted in high risk
populations comprised of smokers and asbestos workers (n=2),
there were significant increases in lung cancer risk associated with
beta carotene supplementation: in the ATBC trial, RR 1.17 (95%
CI 1.02 – 1.34), and in the CARET trial 1.36 (1.07 – 1.72) [93].
In contrast to this interventional data but in agreement with the
biomarker hypothesis, analysis of observational data found that the
pooled RR for lung cancers was decreased in the highest versus the
lowest category of total dietary carotenoid intake for studies
reporting smoking-adjusted risk was 0.79 (95% CI 0.71 – 0.87)
[93]. For intake of beta carotene specifically, there was a non-
significant 8% reduction in smoking-adjusted risk, RR 0.92 (95%
CI 0.83 – 1.01) [93].
This analysis is limited by an exclusive focus on lung cancers
and as such we are unable to draw any conclusions about the
application of retinoids in other cancer types. It is important to
note that there is possible benefits from retinoids in conditions
such as head and neck cancer, mesothelioma, and certain
premalignant conditions. ATRA combined with chemotherapy
has been successful in treating acute promyelocytic leukemia
(APL), inducing remission in what was once a highly lethal
leukemia [25,97]. Reports have shown that classical retinoids
including 13CRA and ATRA may be effective for treatment of
premalignant lesions including leukoplakia, actinic keratosis, and
cervical dysplasia [25,40,98]. In controlled trials on prevention of
head and neck cancer, retinyl palmitate, 13 CRA, and fenretinide
have demonstrated significant response rates [40,99].
With respect to mesothelioma, cancer of the pleural lining of the
lungs, one of the studies reviewed here under primary prevention
found a significantly decreased risk of mesothelioma in the retinol
group, RR 0.24 (0.07-0.86) [61]. A limitation of this study was the
lack of a placebo comparator arm; retinol was instead compared to
beta carotene. It is possible that beta carotene had an overall
adverse effect on disease risk, thereby producing a falsely positive
effect for retinol in comparison, however, this is impossible to
determine.
Strengths of this analysis include a comprehensive and systematic
surveyoftheliterature withaclearfocusonlungcancers.Alllevelsof
evidence, human, observational, and preclinical were included to
achievea broad analysis of anticancer activity of vitaminA/retinoids
in lung cancers, and any possible interactions with chemotherapy
and/or radiation therapy to assess safety alongside efficacy. We are
not aware of another review of vitamin A for lung cancers to date
that has included such an extensive analysis of the available data.
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